BSE:540701

Stock Analysis Report

Executive Summary

Dishman Carbogen Amcis Limited provides contract research and manufacturing services worldwide.

Snowflake

Fundamentals

Flawless balance sheet and undervalued.


Similar Companies

Share Price & News

How has Dishman Carbogen Amcis's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.3%

540701

3.4%

IN Life Sciences

2.3%

IN Market


1 Year Return

-32.6%

540701

18.7%

IN Life Sciences

0.3%

IN Market

Return vs Industry: 540701 underperformed the Indian Life Sciences industry which returned 18.7% over the past year.

Return vs Market: 540701 underperformed the Indian Market which returned 0.3% over the past year.


Shareholder returns

540701IndustryMarket
7 Day0.3%3.4%2.3%
30 Day-11.8%2.6%2.2%
90 Day-24.8%0.3%-2.7%
1 Year-32.6%-32.6%19.6%18.7%2.3%0.3%
3 Yearn/a33.6%30.5%20.7%14.7%
5 Yearn/a127.8%120.2%41.4%28.2%

Price Volatility Vs. Market

How volatile is Dishman Carbogen Amcis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Dishman Carbogen Amcis undervalued compared to its fair value and its price relative to the market?

28.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: 540701 (₹160.8) is trading below our estimate of fair value (₹224.34)

Significantly Undervalued: 540701 is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: 540701 is good value based on its PE Ratio (12.7x) compared to the Life Sciences industry average (23.7x).

PE vs Market: 540701 is good value based on its PE Ratio (12.7x) compared to the Indian market (13.1x).


Price to Earnings Growth Ratio

Low PEG Ratio: 540701 is good value based on its PEG Ratio (0.5x)


Price to Book Ratio

PB vs Industry: 540701 is good value based on its PB Ratio (0.5x) compared to the IN Life Sciences industry average (1.4x).


Next Steps

Future Growth

How is Dishman Carbogen Amcis forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

26.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 540701's forecast earnings growth (26.5% per year) is above the savings rate (7.6%).

Earnings vs Market: 540701's earnings (26.5% per year) are forecast to grow faster than the Indian market (18.2% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 540701's revenue (11.2% per year) is forecast to grow slower than the Indian market (11.4% per year).

High Growth Revenue: 540701's revenue (11.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if 540701's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Dishman Carbogen Amcis performed over the past 5 years?

38.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 540701 has become profitable over the past 5 years, growing earnings by 38.9% per year.

Accelerating Growth: 540701's earnings growth over the past year (13.1%) is below its 5-year average (38.9% per year).

Earnings vs Industry: 540701 earnings growth over the past year (13.1%) exceeded the Life Sciences industry 11.1%.


Return on Equity

High ROE: 540701's Return on Equity (3.8%) is considered low.


Return on Assets

ROA vs Industry: 540701's Return on Assets is below or equal to the Life Sciences industry average last year.


Return on Capital Employed

ROCE Improving: 540701's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Dishman Carbogen Amcis's financial position?


Financial Position Analysis

Short Term Liabilities: 540701's short term assets (₹15.5B) exceeds its short term liabilities (₹12.0B)

Long Term Liabilities: 540701's short term assets (15.5B) exceeds its long term liabilities (7.5B)


Debt to Equity History and Analysis

Debt Level: 540701's debt to equity ratio (15.4%) is considered satisfactory

Reducing Debt: 540701 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: 540701's debt is well covered by operating cash flow (34%).

Interest Coverage: 540701's interest payments on its debt are well covered by EBIT (5.3x coverage).


Balance Sheet

Inventory Level: 540701 has a high level of physical assets or inventory.

Debt Coverage by Assets: 540701's debt is covered by short term assets (assets are 1.875180x debt).


Next Steps

Dividend

What is Dishman Carbogen Amcis's current dividend yield, its reliability and sustainability?

0.12%

Current Dividend Yield


Dividend Yield vs Market

company0.1%marketbottom25%0.6%markettop25%2.5%industryaverage0.5%forecastin3Years1.1%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: 540701's dividend (0.12%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.6%).

High Dividend: 540701's dividend (0.12%) is low compared to the top 25% of dividend payers in the Indian market (2.5%).

Stable Dividend: 540701 is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.

Growing Dividend: 540701 is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: 540701 is not paying a notable dividend for .


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 540701's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

What is the CEO of Dishman Carbogen Amcis's salary, the management and board of directors tenure and is there insider trading?

2.6yrs

Average board tenure


CEO

Arpit Vyas (33yo)

0yrs

Tenure

₹12,000,000

Compensation

Mr. Arpit Janmejay Vyas has been Group Managing Director of Dishman Carbogen Amcis Limited since November 28, 2018 and as its Director since April 7, 2012. He served as Chief Financial Officer and Managing ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Arpit's total compensation is reasonable compared to companies of similar size in the Indian market.

Compensation vs Earnings: Arpit's compensation has been consistent with company performance over the past year.


Board Age and Tenure

2.6yrs

Average Tenure

66yo

Average Age

Experienced Board: 540701's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Mark Griffiths (55yo)

    Director of Global Marketing & Strategy and Director

    • Tenure: 2.6yrs
  • Alan Fischer

    Global Chief Information Officer

    • Tenure: 0yrs
  • Deohooti Vyas (68yo)

    Whole Time Director

    • Tenure: 2.6yrs
    • Compensation: ₹12.00m
  • Janmejay Vyas (68yo)

    Chairman of the Board

    • Tenure: 0yrs
    • Compensation: ₹15.82m
  • Arpit Vyas (33yo)

    Group MD & Director

    • Tenure: 0yrs
    • Compensation: ₹12.00m
  • Stephan Fritschi

    Vice President of Operations

    • Tenure: 0yrs
  • Shrima Dave

    Compliance Officer & Company Secretary

    • Tenure: 0yrs
    • Compensation: ₹698.00k
  • Harshil Dalal

    Global Chief Financial Officer

    • Tenure: 0.9yrs
    • Compensation: ₹8.75m
  • Dharmesh Desai

    GM of Secretarial & Legal

    • Tenure: 0yrs
  • Dieter Thueer

    Global Head of Human Resources

    • Tenure: 0yrs

Board Members

  • Mark Griffiths (55yo)

    Director of Global Marketing & Strategy and Director

    • Tenure: 2.6yrs
  • Ashok Gandhi (80yo)

    Independent Director

    • Tenure: 2.6yrs
    • Compensation: ₹1.48m
  • Deohooti Vyas (68yo)

    Whole Time Director

    • Tenure: 2.6yrs
    • Compensation: ₹12.00m
  • Janmejay Vyas (68yo)

    Chairman of the Board

    • Tenure: 0yrs
    • Compensation: ₹15.82m
  • Sanjay Majmudar (56yo)

    Independent Director

    • Tenure: 2.6yrs
    • Compensation: ₹1.90m
  • Arpit Vyas (33yo)

    Group MD & Director

    • Tenure: 0yrs
    • Compensation: ₹12.00m
  • Subir Das (66yo)

    Independent Director

    • Tenure: 2.6yrs
    • Compensation: ₹1.33m
  • Rajendra Shah (71yo)

    Independent Director

    • Tenure: 2.6yrs
    • Compensation: ₹920.00k
  • Maitri Mehta (37yo)

    Independent Director

    • Tenure: 0.5yrs

Company Information

Dishman Carbogen Amcis Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Dishman Carbogen Amcis Limited
  • Ticker: 540701
  • Exchange: BSE
  • Founded: 2007
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹25.759b
  • Shares outstanding: 161.39m
  • Website: https://www.dishmangroup.com

Location

  • Dishman Carbogen Amcis Limited
  • Dishman Corporate House
  • Opp. Jayantilal Park BRTS Bus Stop
  • Ahmedabad
  • Gujarat
  • 380058
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
540701BSE (Mumbai Stock Exchange)YesEquity SharesININRSep 2017
DCALNSEI (National Stock Exchange of India)YesEquity SharesININRSep 2017

Biography

Dishman Carbogen Amcis Limited provides contract research and manufacturing services worldwide. It manufactures and supplies marketable molecules, such as bulk drugs, intermediates, quaternary ammonium com ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/15 12:54
End of Day Share Price2019/10/15 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.